Navigation Links
Jiangbo Pharmaceuticals Announces New Ticker (JGBO) and CUSIP
Date:5/11/2009

LAIYANG, China, May 11 /PRNewswire-Asia-FirstCall/ -- Jiangbo Pharmaceuticals, Inc. (OTC Bulletin Board: GNPH) (the "Company"), a U.S. pharmaceutical company with its principal operations in the People's Republic of China, today announced that its stock will start trading on the Over the Counter Bulletin Board under the new ticker symbol "JGBO" as of May 12, 2009. The Company's shares will cease trading under the ticker symbol "GNPH" at the end of May 11, 2009.

The Company's shares will be identified under a new CUSIP: 47737 R 10 1.

About Jiangbo Pharmaceuticals, Inc.

Jiangbo Pharmaceuticals, Inc. is a U.S. public company engaged in the research, development, production, marketing and sales of pharmaceutical products in the People's Republic of China. Its operations are located in Eastern China in an Economic Development Zone in Laiyang City, Shandong province. Jiangbo is a major pharmaceutical company in China producing both western and Chinese herbal-based medical drugs in tablet, capsule, granule, syrup and electuary (sticky syrup) form. http://www.jiangbopharma.com

Safe Harbor Statement

Certain statements in this press release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the Company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties. Actual results may differ materially from anticipated or predicted results, and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's ability to obtain raw materials needed in manufacturing, the continuing employment of key employees, the failure risks inherent in testing any new drug, the possibility that regulatory approvals may be delayed or become unavailable, patent or licensing concerns that may include litigation, direct competition from other manufacturers and product obsolescence. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.

    For more information, please contact:

    Jiangbo Pharmaceuticals, Inc.
     Ms. Elsa Sung, CFO
     Phone: +1-954-727-8435
     Email: elsasung@jiangbo.com
     Web:  http://www.jiangbopharma.com

    CCG Investor Relations, Inc.
     Mr. Crocker Coulson, President
     Phone: +1-646-213-1915
     Email: crocker.coulson@ccgir.com
     Web:  http://www.ccgirasia.com

'/>"/>
SOURCE Jiangbo Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Genesis Pharmaceuticals Changes its Name to Jiangbo Pharmaceuticals, Inc. to Reflect its Brand Name
2. Vanda Pharmaceuticals Announces Withdrawal of Director Nominees and Proposal to Liquidate Submitted by Tang Capital
3. Jazz Pharmaceuticals, Inc. Announces First Quarter 2009 Financial Results
4. Photos: Generic Pharmaceuticals Saved $734 Billion over Last Decade
5. VIA Pharmaceuticals Announces Positive Phase 2 Results of VIA-2291 in Cardiovascular Patients Using Serial MDCT Imaging of Coronary Plaque
6. Valeant Pharmaceuticals to Present at Bank of America and Merrill Lynch 2009 Health Care Conference
7. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2009 Financial Results on May 7, 2009
8. Watson Pharmaceuticals Reports First Quarter 2009 Results; Raises 2009 Outlook
9. Conference Call Advisory - NUCRYST Pharmaceuticals Corp. Conference Call to Discuss 2009 First Quarter Results
10. Endo Pharmaceuticals Reports First Quarter 2009 Financial Results
11. Ferring Pharmaceuticals and RESOLVE: The National Infertility Association Join Together to Launch Nurse Liaison Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... ... 5,000 SF expansion and facility enhancement of their 503A compounding pharmacy located in ... the growing demand of physicians and patients throughout the United States for high-quality ...
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... ... for tech innovators, engineers, and scientists from around the world, announces the launch ... users a quick and easy portal to research breakthroughs and trending news, vital ...
(Date:1/19/2017)... ... January 19, 2017 , ... Cosmetic Town, an online plastic surgery ... order to make it easier for their readers to get the information they desire. ... as well as the techniques used on those particular areas. , “We are excited ...
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... ... dermatologist by the American Board of Dermatology and fellowship trained Mohs and cosmetic ... National Institutes of Health, Dr. Li completed his internship in internal medicine at ...
(Date:1/19/2017)... , ... January 19, 2017 , ... ... a doctor who administered fillers that resulted in severe facial disfiguration. After four ... taken on by doctors at UCLA Medical Center, who removed the substances in ...
Breaking Medicine News(10 mins):
(Date:1/20/2017)... -- Research and Markets has announced the addition ... Types, OTC Amplifiers, Diagnostic Instruments), Sales Volume, Company Analysis and ... ... Market Sales Volume, Company Analysis and Forecast to 2022 provides ... The growing prevalence of hearing impairment coupled with ...
(Date:1/20/2017)... BUFFALO, N.Y. , Jan. 20, 2017 /PRNewswire/ ... health programs, has announced the launch of an ... to new guidelines on opioids and helps stem ... Opioids are often prescribed to treat chronic non-cancer ... disease) despite serious risks and lack of evidence ...
(Date:1/19/2017)... , Jan. 19, 2017 ... Summary GlobalData,s new report, "Germany Cataract Surgery Devices ... the Germany Cataract Surgery Devices market. The report provides ... and average prices (USD) within market segements - Phacoemulsification ... also provides company shares and distribution shares data for ...
Breaking Medicine Technology: